Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.44
-0.0300-0.26%
Post-market: 11.35-0.0900-0.79%18:22 EDT
Volume:548.63K
Turnover:6.31M
Market Cap:872.14M
PE:-4.08
High:11.66
Open:11.54
Low:11.29
Close:11.47
Loading ...

Nurix Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $36 From $35

THOMSON REUTERS
·
29 Jan

Oppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

TIPRANKS
·
29 Jan

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
29 Jan

Nurix Therapeutics Fiscal Q4 Net Loss Narrows, Revenue Falls

MT Newswires Live
·
29 Jan

Nurix Therapeutics Q4 EPS $(0.75) Misses $(0.68) Estimate, Sales $13.28M Beat $12.86M Estimate

Benzinga
·
29 Jan

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

THOMSON REUTERS
·
22 Jan

Nurix Therapeutics Price Target Maintained With a $31.00/Share by Stephens & Co.

Dow Jones
·
22 Jan

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Simply Wall St.
·
19 Jan

Barclays Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

TIPRANKS
·
15 Jan

Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

TIPRANKS
·
14 Jan

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

Zacks
·
08 Jan

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Nurix Therapeutics Says Waldenstrom Macroglobulinemia Drug Granted Fast Track Designation by FDA

MT Newswires Live
·
19 Dec 2024

BRIEF-Nurix Therapeutics Receives U.S. FDA Fast Track Designation For Nx-5948

Reuters
·
19 Dec 2024

Nurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948

TIPRANKS
·
19 Dec 2024

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for Nx-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

THOMSON REUTERS
·
19 Dec 2024

Nurix Therapeutics : Anticipate Sharing Additional Clinical Data About Ongoing Phase 1B Expansion Cohort in 2025

THOMSON REUTERS
·
19 Dec 2024

Nurix Therapeutics Inc : H.c. Wainwright Raises Target Price to $35 From $30

THOMSON REUTERS
·
11 Dec 2024

Buy Rating Reaffirmed for Nurix Therapeutics: Promising Clinical Data and Increased Approval Probability for NX-5948

TIPRANKS
·
11 Dec 2024

Nurix Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $35 From $30

THOMSON REUTERS
·
11 Dec 2024